Physician profile
Daniel Jimenez
NPI 1255466801
$19,571.48
in general payments reported to CMS, 2019-2025
45 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,711 · 2020: $2,447 · 2021: $1,938 · 2022: $2,515 · 2023: $2,779 · 2024: $3,598 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,808 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125 · Education: $27.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,808.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.88 |
| Education | $27.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,074.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,613.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,538.23 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $1,428.79 | 2019-2024 | Xarelto |
| Amgen INC. | $1,163.85 | 2019-2025 | Evenity, Repatha, Repatha |
| Pfizer INC. | $1,086.76 | 2019-2025 | |
| Amarin Pharma, INC. | $1,011.69 | 2019-2022 | |
| Glaxosmithkline, LLC. | $718.08 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Corcept Therapeutics | $585.71 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $566.65 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $539.92 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $532.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $428.20 | 2019-2024 | |
| Astellas Pharma US INC | $383.75 | 2019-2021 | |
| Abbvie INC. | $380.99 | 2020-2025 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $297.64 | 2019-2025 | Capvaxive |
| Sumitomo Pharma America, INC. | $281.34 | 2024-2025 | Gemtesa |
| Takeda Pharmaceuticals U.S.A., INC. | $254.32 | 2022-2023 | Cuvitru, Hyqvia |
| Exact Sciences Corporation | $192.64 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $187.23 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $155.66 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $151.83 | 2019-2025 | |
| Boston Scientific Corporation | $148.09 | 2022-2023 | Infinion 16 |
| Abbott Laboratories | $136.39 | 2021-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $92.34 | 2019-2025 | Tymlos |
| Xeris Pharmaceuticals, INC. | $79.30 | 2021-2022 | |
| Welch Allyn | $71.06 | 2021 | |
| Allergan, INC. | $66.35 | 2019-2020 | |
| Dexcom, INC. | $51.93 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $37.90 | 2022-2024 | Zoryve |
| Insulet Corporation | $37.42 | 2023 | Omnipod |
| Averitas Pharma INC. | $26.25 | 2024 | Qutenza |
| Sunovion Pharmaceuticals INC. | $24.48 | 2019 | |
| Echosens North America, INC. | $24.17 | 2025 | Fibroscan |
| Edwards Lifesciences Corporation | $23.21 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Teleflex LLC | $23.06 | 2025 | Urolift |
| Nestle Healthcare Nutrition INC. | $21.75 | 2020 | |
| Endogastric Solutions, INC | $19.83 | 2023 | Esophyx |
| Biosense Webster, INC. | $18.78 | 2021 | |
| Redhill Biopharma INC. | $18.60 | 2022 | |
| Phadia US INC. | $18.24 | 2023 | Immunocap |
| Medtronic, INC. | $17.60 | 2022 | |
| Mannkind Corporation | $16.52 | 2023 | Afrezza |
| Almatica Pharma LLC | $12.58 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.